Everything You Need to Know About NAD Precursors, NAD+ precursor and NR
Let’s talk about precursors NAD+ precursor and NR. What are they?
Precursors are the very things that your body uses to create its own NAD.
Out of all the precursors that exist, the most efficient precursors (ones that take the least amount of energy to convert to NAD) are nicotinamide riboside (NR) and NAD+ precursor.
(And in case you need a refresher, NAD is a crucial coenzyme found in every cell of the body, playing a central role in various biological processes, including energy production, DNA repair, and regulation of gene expression.) As we age, NAD levels tend to decline, which has been linked to various age-related diseases and a decrease in overall vitality.
NAD+ precursor is a molecule composed of a nicotinamide group and a ribose molecule, making it an intermediate in the NAD biosynthetic pathway. When NAD+ precursor is consumed, it can be efficiently converted into NAD in the body, making it a popular choice for NAD supplementation.
But on the other hand, NR, or nicotinamide riboside, is another NAD precursor that has gained prominence. NR is a form of vitamin B3 that can be converted into NAD through a two-step enzymatic process. NR supplementation has shown promise in increasing NAD levels in various preclinical and clinical studies, making it another valuable precursor for those seeking to support their cellular NAD health.
Both of these precursors have been shown to effectively increase NAD+ levels in the body when taken in supplement form. So, which one should you take, and why?
It turns out the answer may be: both.
The use of both NAD+ precursor and NR as NAD precursors can be beneficial because they complement each other in the NAD biosynthesis pathway.
While NAD+ precursor provides a more direct route to NAD+ production, NR can serve as an indirect source by being converted to NAD+ precursor. This redundancy helps maintain NAD levels and allows the body to adapt to varying conditions, ensuring a steady supply of this crucial coenzyme for various cellular processes.
So while NAD+ precursor and NR are both effective precursors to your body’s ability to create its own NAD, different tissues and organs (as well as different microbiomes) may prefer one precursor over the other.
That’s why here at Jinfiniti, our patent formula helps your body create both in our Accuri® Vitality Boost. And, in fact, we’re the only company to do this in the world.
So no matter which type of precursor suits you best, your body is able to create the cellular fuel—the NAD—your body needs.
In summary:
- NAD+ precursor and NR are both precursors to NAD.
- Both precursors safely and effectively increase NAD levels when taken as a supplement.
- Different tissues and organs (and different microbiomes) may prefer one precursor over the other.
- Jinfiniti’s Accuri® Vitality Boost is the only NAD product in the world that helps your body activate both precursors, NAD+ precursor and NR.
The noted biohacker, expert Bryan Johnson, uses our product and has featured Jinfiniti in many of his Instagram posts. One of the most recognized authorities in the biohacking space, he has turned back his aging almost ten years and is a huge fan of Jinfiniti. Johnson recommends both our tests and our Accuri® Vitality Boost.
Our formula also optimizes—not just improves—intracellular NAD for 90% of people alone, which no other NAD supplement can come close to promising.
And that’s why we confidently back it with a 60-day Money Back and Efficacy Guarantee.
Lastly, if you’re interested in going deeper on health-related content, here are a few of our recent posts that you may want to read:
- What Does Peak Performance Look Like?
- 9 Powerful Benefits of Optimizing Your NAD
- Andrew Huberman is Wrong About NAD, NAD+ precursor & Longevity
- Why Optimized, Precision Medicine is the Future
P.S. Want to boost your intracellular NAD levels? Try a 2 week trial of our Jinfiniti Vitality Boost (do 2 scoops per day), use the discount code Blog15 if you’re a new customer for 15% off your 1st order).
